Addition of Rapamycin to Anti-CD3 Antibody Improves Long-Term Glycaemia Control in Diabetic NOD Mice

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Mammalian Target of Rapamycin Integrates Diverse Inputs To Guide the Outcome of Antigen Recognition in T Cells

(2012) A. T. Waickman et al.   JOURNAL OF IMMUNOLOGY

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

(2011) Jean-François Bach   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Evaluating Preclinical Efficacy

(2011) M. A. Atkinson   Science Translational Medicine

Rapamycin Prevents and Breaks the Anti-CD3-Induced Tolerance in NOD Mice

(2009) A. Valle et al.   DIABETES

The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment

(2009) Greg M. Delgoffe et al.   IMMUNITY

Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease

(2009) Matthew M. Hsieh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells

(2008) P. Monti et al.   DIABETES